Q-Line Biotech IPO Exceeds Subscription Target, Non-Institutional Investors Drive Demand

Q-Line Biotech IPO Seeks to Raise ₹214.48 Crore

The initial public offering (IPO) of Q-Line Biotech, a leading supplier of diagnostic equipment and in-vitro diagnostic (IVD) products, began on Thursday, 21 May, and will conclude on Monday, 25 May. The company has set a price band of ₹326 to ₹343 per equity share, with a face value of ₹10 per share. Investors can participate by bidding for a minimum of 400 equity shares, with the option to acquire additional shares in increments of 400.

Founded in 2010, Q-Line Biotech is engaged in the creation, production, and marketing of diagnostic reagents, kits, point-of-care (POC) devices, and consumables, as well as the production, importation, and distribution of diagnostic equipment designed to meet various healthcare requirements. Since 2013, the firm has provided diagnostic equipment and IVD products to diagnostic laboratories, hospitals, and medical colleges.

As of 31 December 2025, the company was capable of producing almost 1.4 million kits in the haematology, clinical chemistry, and rapid/ELISA categories, in addition to having the capacity for 1,200 Selectra machines. In terms of finances, Q-Line Biotech posted a profit of ₹38.7 crore and revenue of ₹232.4 crore for the nine-month period ending December 2025. The profit for the fiscal year 2025 decreased by 18.3% to ₹28.1 crore due to an exceptional loss of ₹16.96 crore; however, revenue rose by 54% to ₹313.8 crore compared to the previous year.

Read also: SMR Jewels IPO Successfully Lists with Institutional Support

The company's promoters hold a 92.24% ownership stake, while the remaining 7.76% of shares are owned by public investors, including Vikas Vijaykumar Khemani, the founder of Carnelian Asset Advisors, who holds a 2.55% stake, and Calliope Capital Advisors, with a 1.37% stake.

As of day 1, the Q-Line Biotech IPO subscription status is 2.44x, with the retail portion subscribed at 1.93x, the Non-Institutional Investor (NII) portion booked at 2.22x, and the Qualified Institutional Buyers (QIBs) portion receiving 3.50x bidding. The company has received bids for 1,01,54,400 shares against 41,58,800 shares on offer at 13:00 IST.

The grey market premium (GMP) for Q-Line Biotech is currently at +135, indicating an estimated listing price of ₹478 apiece, which is 39.36% higher than the IPO price of ₹343. This upward trend is expected to result in a solid listing for the company.

Read also: Zepto Nears $1 Billion Quarterly Net Order Value Milestone Before IPO